AstraZeneca (GB:AZN) has released an update.
AstraZeneca’s Imfinzi has shown promising results in a Phase III trial, offering a significant reduction in the risk of disease recurrence, progression, or death in patients with resectable non-small cell lung cancer (NSCLC). The FDA’s Oncologic Drugs Advisory Committee acknowledged the drug’s potential benefits, and regulatory applications are under review in multiple countries. Imfinzi is already approved in some regions and is part of AstraZeneca’s broad lung cancer treatment portfolio.
For further insights into GB:AZN stock, check out TipRanks’ Stock Analysis page.
